Trichostatin A (TSA)

Name: Trichostatin A (TSA)
Brand: Selleck Chemicals
SKU: S1045
Rating: 5 (194 reviews)

For research use only.

Catalog No.S1045

194 publications

CAS No. 58880-19-6

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Selleck's Trichostatin A (TSA) has been cited by 194 publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2017, 171(4):824-835.e18

PubMed: 29056338 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Cell, 2014, 26(4):534-48

PubMed: 25314079 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00051-4

PubMed: 33651988 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4404

PubMed: 34285225 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(22)e2014681118

PubMed: 34035164 ( click the link to review the publication )

Theranostics, 2021, 11(8):3760-3780

PubMed: 33664860 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108646

PubMed: 33472062 ( click the link to review the publication )

Cancer Lett, 2021, 513:36-49

PubMed: 33991616 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5657

PubMed: 33638154 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3821

PubMed: 34359722 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):532

PubMed: 34031358 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):405

PubMed: 33854041 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):820

PubMed: 34462429 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2021, 12:573824

PubMed: 34349727 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

G3 (Bethesda), 2021, 11(10)jkab265

PubMed: 34568921 ( click the link to review the publication )

Mol Cell Biochem, 2021, 10.1007/s11010-021-04050-3

PubMed: 33515198 ( click the link to review the publication )

Neuroreport, 2021, 32(12):1049-1057

PubMed: 34232131 ( click the link to review the publication )
Nat Metab, 2021, 3(1):75-89

PubMed: 33462516 ( click the link to review the publication )

Sci Adv, 2021, 7(9)eabe5518

PubMed: 33627431 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108646

PubMed: 33472062 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2019.1709762

PubMed: 31986961 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Cell Rep, 2020, 33(11):108507

PubMed: 33326790 ( click the link to review the publication )

mBio, 2020, 11(5)e02343-20

PubMed: 33024042 ( click the link to review the publication )

Free Radic Biol Med, 2020, 10.1016/j.freeradbiomed.2020.01.016

PubMed: 31972340 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Front Immunol, 2020, 3;11:36

PubMed: 32117228 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.0417.2020

PubMed: 33277442 ( click the link to review the publication )

Mol Neurobiol, 2020, 10.1007/s12035-019-01812-5

PubMed: 31919777 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(4):953-969

PubMed: 33299646 ( click the link to review the publication )

Immunol Cell Biol, 2020, 98(4):318-331

PubMed: 31950542 ( click the link to review the publication )

ACS Med Chem Lett, 2020, 11(10):1886-1892

PubMed: 33062169 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

J Immunol Res, 2020, 2020:7263602

PubMed: 33062724 ( click the link to review the publication )
BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

Arch Insect Biochem Physiol, 2020, 103(4):e21649

PubMed: 31777104 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2195-2208

PubMed: 32075759 ( click the link to review the publication )

Theranostics, 2020, 10(17):7747-7757

PubMed: 32685017 ( click the link to review the publication )

Theranostics, 2020, 10(5):2188-2200

PubMed: 32104503 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 74(6):1250-1263

PubMed: 31054974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5792

PubMed: 31857589 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4353

PubMed: 31554795 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5800

PubMed: 31863007 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1707488

PubMed: 31878840 ( click the link to review the publication )

PLoS Biol, 2019, 17(10):e3000461

PubMed: 31600191 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

J Cell Biol, 2019, 218(1):267-284

PubMed: 30538141 ( click the link to review the publication )

J Cell Biol, 2019, 218(12):4017-4029

PubMed: 31645458 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32425

PubMed: 31111958 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

EBioMedicine, 2019, 43:238-252

PubMed: 31047858 ( click the link to review the publication )

J Bone Miner Res, 2019, 10.1002/jbmr.3716

PubMed: 31112333 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):428

PubMed: 31665064 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )
J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz093

PubMed: 31560394 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(4):541-552

PubMed: 30806715 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3442-3452

PubMed: 31432592 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

J Virol, 2019, 93(4)e01896-18

PubMed: 30518648 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4360

PubMed: 30867438 ( click the link to review the publication )

PLoS Comput Biol, 2019, 15(2):e1006826

PubMed: 30785874 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 223:1-8

PubMed: 30862568 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29470

PubMed: 31692090 ( click the link to review the publication )

Cell Adh Migr, 2019, 13(1):285-292

PubMed: 31271097 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(5):822-832

PubMed: 30860602 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3209-3218

PubMed: 31002353 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):285-293

PubMed: 30387821 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Reprod Fertil Dev, 2019, 31(3):473-481

PubMed: 30301509 ( click the link to review the publication )
Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

bioRxiv, 2019, 10.1101/748129

PubMed: N/A ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4098-4114

PubMed: 30124467 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Mol Ther, 2018, 26(7):1828-1839

PubMed: 29730197 ( click the link to review the publication )

Oncogene, 2018, 37(8):1049-1061

PubMed: 29084211 ( click the link to review the publication )

Oncogene, 2018, 37(50):6414-6424

PubMed: 30068939 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Oncol, 2018, 12(5):724-755

PubMed: 29577611 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Plant Cell Rep, 2018, 37(1):115-123

PubMed: 28939922 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Int Immunopharmacol, 2018, 65:303-311

PubMed: 30342347 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 503(2):420-427

PubMed: 29649477 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Med Sci Monit, 2018, 24:461-472

PubMed: 29363667 ( click the link to review the publication )

Methods Mol Biol, 2018, 1755:179-195

PubMed: 29671271 ( click the link to review the publication )
Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Cell Res, 2017, 27(7):898-915

PubMed: 28497810 ( click the link to review the publication )

Mol Cell, 2017, 67(4):566-578

PubMed: 28803781 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Plant Physiol, 2017, 175(3):1484-1496

PubMed: 28972079 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2017, 26(9):1411-1419

PubMed: 28619831 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Sci Rep, 2017, 7:46195

PubMed: 28387374 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

J Diabetes Res, 2017, 2017:8208065

PubMed: 28191472 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 485(2):454-460

PubMed: 28192116 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1978-88

PubMed: 26634271 ( click the link to review the publication )
Thorax, 2016, 633-45

PubMed: 27071418 ( click the link to review the publication )

EMBO Rep, 2016, 17(7):999-1012

PubMed: 27154402 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Free Radic Biol Med, 2016, 99:167-178

PubMed: 27498117 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4085727

PubMed: 27746856 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2591-607

PubMed: 27082124 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):886

PubMed: 27842508 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1586

PubMed: 25569103 ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: 25303559 ( click the link to review the publication )
Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Chem Biol Interact, 2015, 242:227-34

PubMed: 26482938 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120587

PubMed: 25807249 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EMBO J, 2014, 34(1):115-29

PubMed: 25398909 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Development, 2014, 141(7):1534-43

PubMed: 24598165 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-16

PubMed: 24200994 ( click the link to review the publication )

Life Sci, 2014, 99(1-2):31-6

PubMed: 24486299 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):574-80

PubMed: 24607957 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6701-15

PubMed: 25149533 ( click the link to review the publication )

Sci Rep, 2014, 4:4663

PubMed: 24722541 ( click the link to review the publication )

Methods Mol Biol, 2014, 1156:431-43

PubMed: 24792006 ( click the link to review the publication )

Science, 2014, 344(6183):1252304

PubMed: 24727982 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Plant J, 2013, 74(5):815-28

PubMed: 23464703 ( click the link to review the publication )

Cytokine, 2013, 65(2):121-5

PubMed: 24373940 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )
Epigenetics, 2012, 7(10):1161-72

PubMed: 22965008 ( click the link to review the publication )

Adv Genet, 2010, 70:341-86

PubMed: 20920755 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Targets

HDAC ^[1]
(Cell-free assay)

~1.8 nM

In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. ^[1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. ^[2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HeLa	NEPkNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3YNFNKOTBxM{CvOVAhdk1?	NHzMVJk4OiCq	NYDS[INPTE2VTx?=	NEXrbJBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O\|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk>	NUO4fG5kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlU4PDhpPkKzNVY2PzR6PD;hQi=>
HeLa	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml36NlAhdk1?	NHnqN\|I4OiCq	Mkj6SG1UVw>?	NX7hV\|JYUUN3MDDv[kAzOG6P	NEXhU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2OVc1QCd-MkOxOlU4PDh:L3G+
HeLa	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j2elQxKG6P	MVy0PEBp	MlLzSG1UVw>?	NVLGT3FZUUN3MDDv[kA1OG6P	M{jS[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MU[1O\|Q5Lz5{M{G2OVc1QDxxYU6=
HeLa	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HxUlExOCCwTR?=	NUjHSmNWOjRiaB?=	M1LmXGROW09?	NHHBWHJKSzVyIH;mJFExOG6P	NULWRpVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlU4PDhpPkKzNVY2PzR6PD;hQi=>
Caco-2	NGHGcmhHfW6ldHnvckBCe3OjeR?=	NHzRPW4yKML3TdMg	NIHxWmwzPCCq		NVrFU\|l2\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO\|aX;u	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF7NUC3NEc,OjNzOUWwO\|A9N2F-
HTK	NHfTcW1HfW6ldHnvckBCe3OjeR?=	MnvQNVAxNThyMH7N	NYLVNWx5PzJiaB?=		NIXtPYJjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU\|LDqEGlY4XteYxifGmxbh?=	MnfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OESwNFIoRjJ\|Mki0NFAzRC:jPh?=
HTK	NF\5b2ZHfW6ldHnvckBCe3OjeR?=	MVu0NFAhdk1?	MWW3NkBp		M1G3ZolvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44>	MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OESwNFIoRjJ\|Mki0NFAzRC:jPh?=
HEK293	NIjjdHpHfW6ldHnvckBCe3OjeR?=	M1nOW\|EhyrWPwrC=	M1rLWlE5KGkEoB?=		NX\0V2h7cW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC\|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?=	Mn3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OES4OFgoRjJ\|Mki0PFQ5RC:jPh?=
SH-SY5Y	M4PVcWZ2dmO2aX;uJGF{e2G7	M4rocVI2OCCwTR?=	M{TTTVE3KGh?		M2rIO4Np[W6pZYOg[ZhxemW\|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi=	Mn;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|Mk[0NlIoRjJ\|M{K2OFIzRC:jPh?=
THP1	M1vlcGFxd3C2b4Ppd{BCe3OjeR?=	M2\oXVEh\|ryP	NH3jNFEzPCCq		M1z4Tolv\HWlZYRCpINmdGxiZHXheIg>	NXvscoliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFA2OTlpPkKzOFAxPTF7PD;hQi=>
K562	NF3DZYNCeG:ydH;zbZMhSXO\|YYm=	NYO4W4hoOSEQvF2=	NGTKSZczPCCq		NEPPN2NqdmS3Y3XzxsBk\WyuIHTlZZRp	NUDvN\|NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFA2OTlpPkKzOFAxPTF7PD;hQi=>
Kazumi	M1XVNGFxd3C2b4Ppd{BCe3OjeR?=	MmLCNUDPxE1?	NIfpc4gzPCCq		NUfXVWtkcW6mdXPld:Kh[2WubDDk[YF1cA>?	NUf1XmQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFA2OTlpPkKzOFAxPTF7PD;hQi=>
KG1	M1j4cWFxd3C2b4Ppd{BCe3OjeR?=	M3Pm[FEh\|ryP	MUmyOEBp		MVrpcoR2[2W\|wrDj[YxtKGSnYYTo	NXHyWYJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFA2OTlpPkKzOFAxPTF7PD;hQi=>
HL60	NXTIU5BVSXCxcITvd4l{KEG\|c3H5	MWKxJO69VQ>?	NUC1fINOOjRiaB?=		MonWbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	NW\BVYZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFA2OTlpPkKzOFAxPTF7PD;hQi=>
HEL	MlnDSpVv[3Srb36gRZN{[Xl?	NGC1NW4xNjVizszN	NWLCeFZLOjRiaB?=	M3LrSYV1cGGwb3y=	MV;k[YNz\WG\|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=>	M1u1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEOwPVU4Lz5{M{SzNFk2PzxxYU6=
K562	MoTDSpVv[3Srb36gRZN{[Xl?	M4W0SVAvPSEQvF2=	NWHuS5JKOjRiaB?=	M3W2Z4V1cGGwb3y=	M2\ybYRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv	NVTXfIY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|A6PTdpPkKzOFMxQTV5PD;hQi=>
LM8	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HhWVAvOyEQvF2=	MkWyNVIuQTZiaB?=	M1jRcmROW09?	M{G5XIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6=	NHrLdWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S1NVgyPyd-MkO0OVE5OTd:L3G+
MG-63	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOwMlMh\|ryP	M{HRfVEzNTl4IHi=	NFHuVnBFVVOR	NIG3XYNqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu	NHzvPYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S1NVgyPyd-MkO0OVE5OTd:L3G+
H1299	NVj4XFV4TnWwY4Tpc44hSXO\|YYm=	M4LIXFAvPSEQvF2=	MlzwOFghcA>?	M2PYZ2ROW09?	NIi0XY5qdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?=	MmWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NkG5O\|UoRjJ\|NE[xPVc2RC:jPh?=
H1299	MYLGeY5kfGmxbjDBd5NigQ>?	NIS1cGkxNjVizszN	MnvDOFghcA>?	MnXHSG1UVw>?	MX7pcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR4MUm3OUc,OjN2NkG5O\|U9N2F-
H1299	MWHGeY5kfGmxbjDBd5NigQ>?	NHTlcGExNjN\|4pETNeKhyrWP	NFXFPXEzPC92ODDo	M1HaOGROW09?	MX3pcoNz\WG\|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7	NH:1fZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S2NVk4PSd-MkO0OlE6PzV:L3G+
MCF7	Moj4SpVv[3Srb36gRZN{[Xl?	MVWwMlA2NTJizszN	NE[5SXQzPCCq		M1jES5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{	Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{C1OFAoRjJ\|NEewOVQxRC:jPh?=
ARN8	NUjVNINbTnWwY4Tpc44hSXO\|YYm=	MYmwMlA2NTJizszN	M{XybVI1KGh?		M4eyXJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5MEW0NEc,OjN2N{C1OFA9N2F-
U373	NUT0b4MxTnWwY4Tpc44hSXO\|YYm=	NF7Pc28xNjJ3L{CuOU8yKM7:TR?=	M1znUFI1KGh?		M{e3ZYlv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF	NH\uPZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OFE4OSd-MkO0O\|QyPzF:L3G+
HASMCs	MWDGeY5kfGmxbjDBd5NigQ>?	MVqwMVUxOCCwTR?=	MX22JIQ>		M2LEdoRwf25vcnXneYxifGW\|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzOES2O{c,OjN3MUi0Olc9N2F-
MFE296	MULGeY5kfGmxbjDBd5NigQ>?	NFrhUmU2ODBibl2=	M2[3fFUh\A>?	NXnOO\|ZyTE2VTx?=	Ml3ZbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MEe2PUc,OjN3M{C3Olk9N2F-
EN1	MVPGeY5kfGmxbjDBd5NigQ>?	Mn3rOVAxKG6P	MUG1JIQ>	MWTEUXNQ	Mkj3bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	NXHpb5ZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|A4PjlpPkKzOVMxPzZ7PD;hQi=>
HEC1A	MkjxSpVv[3Srb36gRZN{[Xl?	Mom3OVAxKG6P	MkLBOUBl	MlLBSG1UVw>?	MoHubY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	NGrYV449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNFc3QSd-MkO1N\|A4Pjl:L3G+
ECC1	NV7FVmE5TnWwY4Tpc44hSXO\|YYm=	MYC1NFAhdk1?	MVe1JIQ>	MmDySG1UVw>?	MoHmbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MEe2PUc,OjN3M{C3Olk9N2F-
AGS	NFz1W4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrXNE4xOTVvMTFOwG0>	NHi0flQ4OiCq		Mnf0bY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	NVfZ[GsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFUxOjRpPkKzO\|Q2ODJ2PD;hQi=>
Huh7	Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H2UFEh\|ryP	MnHBNlQhcA>?	NFK5fIpFVVOR	NHrWZZFz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2M{mzN{c,OjN4NEO5N\|M9N2F-
Lovo	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUH4c452OC5{L{GuNE82NjBizszN	MYexNk8zPC9\|Nj:0PEBp		NWrWVFljcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	M4T6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{ewNFAxLz5{M{e3NFAxODxxYU6=
HCT1	NX3URmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjGdnB4OC5{L{GuNE82NjBizszN	NGi5bGoyOi9{ND:zOk81QCCq		NUXn[Hh2cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NYLMd3Y2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3O\|AxODBpPkKzO\|cxODByPD;hQi=>
SUM190PT	NYTWS4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK0SVQ2OC9zMECvNlUxKG6P	MX20PEBp	MWHEUXNQ	MYnpcoR2[2W\|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk>	MlnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK2N\|goRjJ\|N{myOlM5RC:jPh?=
SUM149PT	NYL3SGNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3iVJJvOi95LkWvNVAh\|ryP	MlfsOFghcA>?	MX7EUXNQ	NHfQT2dqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6\|ZX7zbZRqfmWueR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7Mk[zPEc,OjN5OUK2N\|g9N2F-
H1299	NV:zNGNISXCxcITvd4l{KEG\|c3H5	NVPtN3U3OC53L{Gg{txO	Mn;ROFghcA>?	NV75[Fl7\XSqYX7vcC=>	M33nS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NEHiNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2O\|k6OSd-MkO4Olc6QTF:L3G+
A549	NVHkTYFXSXCxcITvd4l{KEG\|c3H5	M1vXWFAvPS9zIN88US=>	NX33ZmltPDhiaB?=	M3zQZYV1cGGwb3y=	NVrjOGFHcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh4N{m5NUc,OjN6Nke5PVE9N2F-
H1299	M4O5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTMN5BoOC5{NT:wMlUwOSEQvF2=	MkD4NlQwPDhxN{KgbC=>	Ml\n[ZRp[W6xbB?=	MmDBbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NF3JSYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2O\|k6OSd-MkO4Olc6QTF:L3G+
A549	NUO0WIN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHIRYQ1OC5{NT:wMlUwOSEQvF2=	MYGyOE81QC95MjDo	MX;leIhidm:u	M3nNXIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	M164T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OE[3PVkyLz5{M{i2O\|k6OTxxYU6=
H1299	NFTqN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfGWo5vOcLizszNxsA>	NHXGb40zPC92OD:3NkBp	NH2xW\|lmfGijbn;s	MmXxbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp	NYHQe282RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVY3ODlpPkKzPVE3PjB7PD;hQi=>
PMNs	M3fKVGZ2dmO2aX;uJGF{e2G7	NULQNXd6OzBibl2=	NHrIeow1QCCq		MoLNbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5	NXPP[GNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PFg3OTdpPkKzPVg5PjF5PD;hQi=>
CA46	NWfIWnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33LW\|MwPi9zMj:yOE81QCCwTR?=	NWS0c48{PDhiaB?=		NWrWe3VGcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?=	NYf0To9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlQ6PTFpPkK0NFY1QTVzPD;hQi=>
HCT116	NGW2fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;vNE4zKM7:TR?=	MXyxNkBp		Mni0[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36=	NYXkZYpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlIzOzFpPkK0NVIzOjNzPD;hQi=>
HLEB3	NGPHOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\qNE41NzBwODFOwG0>	NIXvbYw1QCCq	MYfEUXNQ	MoT6bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M2HmRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUW3PFc5Lz5{NEG1O\|g4QDxxYU6=
SRA01/04	M1T4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33HS\|AvPC9yLkig{txO	NWCy[YFsPDhiaB?=	MoDVSG1UVw>?	M{[1OYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NFf3bog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1O\|g4QCd-MkSxOVc5Pzh:L3G+
HLEB3	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXXUY5wOC5{IN88US=>	MlrGOFghcA>?	M2H6SWROW09?	MUfzeZBxemW\|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=>	NV3jfG1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVc5PzhpPkK0NVU4QDd6PD;hQi=>
SRA01/04	NVzWUY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXVeIdOOC5{IN88US=>	MkP2OFghcA>?	M3u0VWROW09?	MlzXd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM>	NUHnVHI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVc5PzhpPkK0NVU4QDd6PD;hQi=>
A2780	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n5OFAvODVvMjFOwG0>	MYSxNE8zPC92ODDo	NUnUOJZ2TE2VTx?=	M3XCWI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NG[wU\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyN\|gxOSd-MkSyNlM5ODF:L3G+
SKOV3	NUHqNoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHBNE4xPS1{IN88US=>	NVPtSHpzOTBxMkSvOFghcA>?	MWTEUXNQ	NYTFUXBvdWWmaXH0[ZMh\3Kxd4ToJIFzemW\|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NIHFboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyN\|gxOSd-MkSyNlM5ODF:L3G+
Huh7	MWrGeY5kfGmxbjDBd5NigQ>?	NVLh[IlzOC5zL{CuOU8yNjBizszN	MmflNlRp		NXfHPXJ3e3WycILld5NmeyC\VFjER\|Ih\2WwZTDlfJBz\XO\|aX;u	NUSyNINGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3PzJpPkK0NlY6Pjd{PD;hQi=>
hMSCs	NGTRTINHfW6ldHnvckBCe3OjeR?=	NX63NYF3Pi5{NTDuUS=>	MYqyOEBp	M{f3d2ROW09?	NIPDfJl{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz	NWHC[lQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVI{PTZpPkK0N\|EzOzV4PD;hQi=>
HT29	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUKxPFAhdk1?	NF7X[FE4OiCq		NYDleXVVUUN3MDDv[kAyQDBibl2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN4OEK2OUc,OjR\|NkiyOlU9N2F-
RPE	NWK0TYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPvNE4zNzBwND:wMlgwOSEQvF2=	MUCyOE81QC95MjDo	NH\zPG9FVVOR	MmfnbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3Nk[wNkc,OjR2NU[2NFI9N2F-
U87 GBM	MkC2SpVv[3Srb36gRZN{[Xl?	MY[xNFAwPTByIF7t	MkT3OFghcA>?	NE\1UHgyODBnIHX0bIFvd2x?	M2TNN2lv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR4NEi0NUc,OjR2NkS4OFE9N2F-
U87 GBM	NXTmO5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\6V5UyODBxM{CwM\|UxOCCwTR?=	NXzWU4lJPzJiaB?=	MYmxNFAmKGW2aHHuc4w>	M12ydpJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=>	NXvEdVJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OlQ5PDFpPkK0OFY1QDRzPD;hQi=>
ACP03	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXiyOVAwOzVyL{WwNI5O	MnnXNlRp		M4fHRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	NH6ycI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[2PFU1Pyd-MkS2Olg2PDd:L3G+
ACP02	NXL4cldJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInkWVEzPTBxM{WwM\|UxOG6P	MWSyOIg>		M4HnS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	NWnOO5B3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2Olg2PDdpPkK0OlY5PTR5PD;hQi=>
HeLa	NHXFdlZHfW6ldHnvckBCe3OjeR?=	M1r6OlFuVQ>?	MnG3NE42cA>?		M1vh[4Fjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?=	NHXOVWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewO\|Q4PCd-MkS3NFc1PzR:L3G+
HMEC-1	NYnhS3VGTnWwY4Tpc44hSXO\|YYm=	MXKzNFBvVQ>?	NEnEbmQzPGh?		MlnQbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=>	M2rmU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{GwOlMyLz5{NEexNFY{OTxxYU6=
HeLa	NXWzfm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLzUYYz\|ryP	Ml\xOFhp		M1vyS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW=	M{nvS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OES2NVM2Lz5{NEi0OlE{PTxxYU6=
LNCaP	M4DzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[3flExOC1zMECwcm0>	NIK4U3YzPGh?		NXLBUFVRUUN3MDDv[kA{ODCwTR?=	MlX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS2OVgoRjJ2OEW0OlU5RC:jPh?=
PC3	NHrWOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjLSY0yODBvMUCwNI5O	NIDJW24zPGh?		MWjJR\|UxKG:oIEOwNI5O	MmnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS2OVgoRjJ2OEW0OlU5RC:jPh?=
CNE2	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\LNVAxNTZyMH7N	M3Xv[lI1NzR6L{eybC=>		M4fUSYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mnv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7Nkm5NFEoRjJ2OU[5PVAyRC:jPh?=
HeLa	M1nSS2Z2dmO2aX;uJGF{e2G7	M3\je\|I2OG6P	MWSxOog>	NV\Id2Z6TE2VTx?=	MXLpcoNz\WG\|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi	Mn3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMU[2PFgoRjJ3MUG2Olg5RC:jPh?=
A549	NFnI[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HBblAvODFvMD65{txO	NES2SnQ4Omh?	MYTEUXNQ	MU\JR\|UxKG:oIECuNFbPxE1?	MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNkm0PVEoRjJ3MU[5OFkyRC:jPh?=
SKOV-3	NEn0U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe0OJMxNjBzLUCuPe69VQ>?	MV23Nog>	NXLZSIJmTE2VTx?=	NIHrOXhKSzVyIH;mJFAvOzMQvF2=	NX3YeldsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOlk1QTFpPkK1NVY6PDlzPD;hQi=>
A549	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXLeJM2OC5zLUJOwG0>	Mn\kOFhp	NXrLXlVFTE2VTx?=	MmD4TWM2OCCxZjCwMlI5\|ryP	M2XWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MU[5OFkyLz5{NUG2PVQ6OTxxYU6=
SKOV-3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XhNlAvOS1zzszN	M1jiXVQ5cA>?	MlnRSG1UVw>?	M4jlT2lEPTBib3[gNE44\|ryP	NHS3c3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG2PVQ6OSd-MkWxOlk1QTF:L3G+
A549	M4nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[xMVEx\|ryP	NWjmfYRUOjSq	MojkSG1UVw>?	NUTHXmduUUN3MDDv[kA{NjMQvF2=	M4n5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MU[5OFkyLz5{NUG2PVQ6OTxxYU6=
SKOV-3	NGPFR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYSxMVEx\|ryP	NF\ueHAzPGh?	M2O4WGROW09?	M1K3RWlEPTBib3[gOU43\|ryP	M2mzfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MU[5OFkyLz5{NUG2PVQ6OTxxYU6=
MCF7	NE\lc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmP3NE03ODCwTR?=	NXnGdJczOjSq	NULXcGtUTE2VTx?=	NGr3VVJKSzVyIH;mJFc2dk1?	M4jCPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUmyO\|IyLz5{NUG5NlczOTxxYU6=
MDA-MB-231	NVPiZ5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjsNVhZOC14MEDuUS=>	MnXUNlRp	NYnjWlJITE2VTx?=	NUfpSFYzUUN3MDDv[kAyODCwTR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkeyNUc,OjVzOUK3NlE9N2F-
A431	NWrmdY5rTnWwY4Tpc44hSXO\|YYm=	Mkj6OVBvVQ>?	M332cVIwPi9zMj:yOIg>	MoTNSG1UVw>?	MYDhZ5RqfmG2ZYOgdFIyKGGwZDDpcohq[mm2czDBWGY{KGW6cILld5Nqd25?	M1n2bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{exNFY6Lz5{NUO3NVA3QTxxYU6=
A431	M{C3O2Fxd3C2b4Ppd{BCe3OjeR?=	Mnv6Nk8yOC93MD:xNFBvVQ>?	M4LhUVQ5cA>?	MkLISG1UVw>?	M1TJSYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?=	NEHxPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3NVA3QSd-MkWzO\|ExPjl:L3G+
PC3	NXHSSZNLTnWwY4Tpc44hSXO\|YYm=	M4S0ZVAvOc7:TR?=	NWrCUnhiPDiq	NGT1NXpFVVOR	MoPZbY5lfWOnczDpcoNz\WG\|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NEm5O{c,OjV2M{S5PVc9N2F-
SW480	NUfpNmF5TnWwY4Tpc44hSXO\|YYm=	M17Nc\|AvOc7:TR?=	NYTKWmRvPDiq	M3zFZWROW09?	M4HieIlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ?	NYL5cGw6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Q6QTdpPkK1OFM1QTl5PD;hQi=>
PC3	MVPGeY5kfGmxbjDBd5NigQ>?	NGLCPZIxNjIQvF2=	MXu0PIg>	M2LHSGROW09?	MYrheJRmdnWjdHXzJIlvfmG\|aX;uJIFv\CCvaXfyZZRqd25?	M1\LfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO0PVk4Lz5{NUSzOFk6PzxxYU6=
PC3	NUDOOmp6TnWwY4Tpc44hSXO\|YYm=	NGG3[JoxNjIQvF2=	MYK0PIg>	MmPESG1UVw>?	MYTy[ZZmenOnczDFUXQ>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NEm5O{c,OjV2M{S5PVc9N2F-
SW480	NX\M[osyTnWwY4Tpc44hSXO\|YYm=	MmLmNE4y\|ryP	MUC0PIg>	MUnEUXNQ	MXzheJRmdnWjdHXzJIlvfmG\|aX;uJIFv\CCvaXfyZZRqd25?	MlTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{S5PVcoRjJ3NEO0PVk4RC:jPh?=
SW480	MkfkSpVv[3Srb36gRZN{[Xl?	NH7FW3QxNjIQvF2=	MoDoOFhp	MlS0SG1UVw>?	NFHiPY1z\X[ncoPld{BGVVR?	NXO5VVBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Q6QTdpPkK1OFM1QTl5PD;hQi=>
MEFs	Ml;ESpVv[3Srb36gRZN{[Xl?	M1nnR\|XPxE1?	MmTkNVZp		MUnpcoNz\WG\|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44>	NF73[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4NlY{PCd-MkW0PFI3OzR:L3G+
TE13	NUS5UYp5SXCxcITvd4l{KEG\|c3H5	NUizfppJOC5\|zszN	NH7LcXQzPGh?		M1HWXYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25?	NVnWSHh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|k3PjVpPkK1OVc6PjZ3PD;hQi=>
TE13	MWPGeY5kfGmxbjDBd5NigQ>?	NVzCU2RROC5\|zszN	NGLKb5gzPGh?		M3:xVZVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs	MmHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{m2OlUoRjJ3NUe5OlY2RC:jPh?=
HEK 293	M1[0NGZ2dmO2aX;uJGF{e2G7	MV:wMlfPxE1?	NEDPWGozPGh?	NV;WfZI1\XSqYX7vcC=>	M{[xToVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V?	M363blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i3NFc6Lz5{NUe4O\|A4QTxxYU6=
MDA-MB-231	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\sNlUuPDByIH7N	NFjQT4g1QCCq		NW\HcXRqUUN3MDDv[kAzPjNwMn7NxsA>	M1ezOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEW1NVk5Lz5{M{C1OVE6QDxxYU6=
MCF-7	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3W2TFI2NTRyMDDuUS=>	MUe0PEBp		NIrQbHhKSzVyIH;mJFIzOC52bl2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3NUG5PEc,OjNyNUWxPVg9N2F-
ECC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:xNFAhdk1?	MWOyOEBp	MUPleIhidm:u	NGK3cpNqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB\|NTW=	M1;jW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEK4PFA{Lz5{M{CyPFgxOzxxYU6=
HEC-1A	NYKyN5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Py[FExOCCwTR?=	NI\ZdHgzPCCq	NUDBTmNT\XSqYX7vcC=>	M3jNbYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?=	M17vW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEK4PFA{Lz5{M{CyPFgxOzxxYU6=
NHAC-kn	NW\0WHplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXyxNE8yODBxNUCwJI5O	NEDzdooyOiCq	NIrhRZJFVVOR	NXPxXXhDUUN3MDDv[kA2ODCwTR?=	NUKxVWRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVc5PzFpPkKzNFE4QDdzPD;hQi=>
A549	M4n4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTvc2hUOjVyIH7N	NGC1VGg3NTd{IHi=	M17tfmROW09?	M3\LOoNifXOnczDhJIdz\WG2ZYKgbY5pcWKrdH;yfUBm\m[nY4SgZ49u[mmwZTD3bZRpKFS[VDDvdkBmemyxdHnubYI>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl7NEe4NEc,OjJ7OUS3PFA9N2F-
MG-63	NGG3OHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuzNFAhdk1?	M4LZW\|EzKGh?	M4OyWGROW09?	M{jXVolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd7OUOzPEc,OjJ5OUmzN\|g9N2F-
MG-63	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6zNFAhdk1?	MlLXNlQhcA>?	NVPpNHN6TE2VTx?=	MkHGbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>?	MornQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OUmzN\|goRjJ{N{m5N\|M5RC:jPh?=
MG-63	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP5dZI{ODBibl2=	M1ywN\|Q5KGh?	NGrUNmlFVVOR	NUOxcY5VcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd7OUOzPEc,OjJ5OUmzN\|g9N2F-
HL60	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUG3WnNLOTVyLUO1NEBvVQ>?	NVXIdYxmOjRiaB?=		M1zmN4lv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0>	M3iyOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{WzO\|M6Lz5{Mke1N\|c{QTxxYU6=
U937	NYG5[mdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULLe3RQOTVyLUO1NEBvVQ>?	M1:w[VI1KGh?		MWrpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N	NX;qWZYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OVM4OzlpPkKyO\|U{PzN7PD;hQi=>
SCC-6	NHXPfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfhZVAzODBvM{KwNEBvVQ>?	M1rQXVEzNzJ2L{S4JIg>	NHfkdHFFVVOR	NGTOfJNqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	M4m1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyN\|IyLz5{MkW1NlMzOTxxYU6=
U87	NWTK[GhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{T0S\|ExOC1\|MECgcoc>	MVOyOEBp		NXi2OoVXcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne=	NVnzbVNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|A5PDlpPkKyNlcxQDR7PD;hQi=>
K562	MY\GeY5kfGmxbjDBd5NigQ>?	MVSxJO69VQ>?	MXqxNkBp	MV;EUXNQ	NEjPXHVmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=>	M2nlWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUe5NVk5Lz5{MkG3PVE6QDxxYU6=
Reh	M1LU[2Z2dmO2aX;uJGF{e2G7	MXywMlMwOSEQvF2=	M{Lh[\|EzKGh?	NW\QSoIyTE2VTx?=	MkHp[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF5OUG5PEc,OjJzN{mxPVg9N2F-
Mv1Lu	Mlf4SpVv[3Srb36gZZN{[Xl?		MlPyNVghcHK\|		M{\sSWlv\HWldHnvckBw\iC5aXzkMZR6eGVicEKxJJBzd22xdHXyJIFkfGm4YYTpc44hcW5ibXnub{BOfjGOdTDj[YxteyCjZoTldkAyQCCqcoOgZpkhdHWlaX\ldoF{\SCjc4PhfUBz\WyjdHn2[UB1dyCkYYPhcEBt\X[nbDygSWMyODByIE2gNE4yQSEQvF2u	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzh6MUKzNkc,OTd6OEGyN\|I9N2F-
HeLa	Ml32SpVv[3Srb36gZZN{[Xl?		MmfUNlQhcHK\|		MnvvTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgNlQhcHK\|LDDFR\|ExODBiPTCwMlAyOTVizszNMi=>	M4nSWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{m3PFI3Lz5zOEO5O\|gzPjxxYU6=
Mv1Lu	NXrJNY9yTnWwY4Tpc44h[XO\|YYm=		M2HSUlI1KGi{cx?=		M2XPPGlv[3KnYYPlJIlvKGi3bXHuJJdqdGRidInw[UBxOjFicILveIVqdiCneIDy[ZN{cW:wIHnuJI1qdmtiTY[xUJUh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IICyNUBxem:vb4TldkBie3OjeTygSWMyODByIE2gNE4xOiEQvF2u	M4jYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OVc5Lz5{NEm5O\|U4QDxxYU6=
HCT 116	M3fPeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7				MoryTY4hfmm2cn:gZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiClb3zvckBk[W6lZYKgTGNVKDFzNjDj[YxteyCmZYTldo1qdmWmIHL5JG1OXCCjc4PhfUwhTUN3MDC9JFEh\|ryPLh?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTV7N{SxN{c,OTF3OUe0NVM9N2F-
T24	M1jQbGZ2dmO2aX;uJIF{e2G7				M{DJVmNwdmOnboTyZZRqd25ib3[gZ49ueG:3bnSgdoVyfWm{ZXSg[o9zKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWtOEBqdiCqdX3hckBVOjRiY3HuZ4VzKGOnbHzzMEBGSzVyIE2gNUDPxE1w	NWW0cZp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1PVc1OTNpPkGxOVk4PDF\|PD;hQi=>
T24	MXXGeY5kfGmxbjDhd5NigQ>?				M4PScGlvcGmkaYTpc44hd2ZiYXPleJlt[XSrb36gc4YhcGm\|dH;u[U01KGmwIHj1cYFvKFRvMkSgZ4Fv[2W{IHPlcIx{NCCHQ{WwJF0hOSEQvF2u	NWPkRXZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2NVM{OTJpPkG0OlE{OzF{PD;hQi=>
T24	M4m3WWZ2dmO2aX;uJIF{e2G7				MXnJcohq[mm2aX;uJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWtOEBqdiCqdX3hckBVNTJ2IHPhcoNmeiClZXzsd{whTUN3MDC9JFQh\|ryPLh?=	NFi5c\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[xN\|MyOid-MUS2NVM{OTJ:L3G+
T24	Mm[ySpVv[3Srb36gZZN{[Xl?				NGH4bGxKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBi[2W2eXzheIlwdiCrbjDoeY1idiCWMkSgZ4VtdHNuIFXDOVAhRSByLkCxJO69VS5?	MnnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUG0OlYoRjF7MUGxOFY3RC:jPh?=
T24	M{W2Z2Z2dmO2aX;uJIF{e2G7				MoHMTY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36gbY4hcHWvYX6gWFI1KGOnbHzzMEBGSzVyIE2gNE4xOSEQvF2u	M2PVbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUGxOFY3Lz5zOUGxNVQ3PjxxYU6=
HepG2	MoflSpVv[3Srb36gZZN{[Xl?				MkX6WZAuemWpdXzheIlwdiCxZjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHlib3[gbJVu[W5iQ1zBMVEheHKxbX;0[ZIhemWpaX;uJE0yODV3IITvJE03OmKyIITyZY5{\mWldHXkJIlvKEincFeyJINmdGy\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwM{ig{txONg>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NkGwNkc,OjV3NU[xNFI9N2F-
HeLa	NXi1RWVWTnWwY4Tpc44h[XO\|YYm=				MlHhTY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWkdXzpckBl\WGlZYT5cIF1cW:wIHnuZ5Vj[XSnZDDmc5Ihd3[ncn7p[4h1KGK7IHPFUGlUSSxiRVO1NEA:KDBwMEC1NkDPxE1w	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZzMUmxPUc,OjZ4MUG5NVk9N2F-
HL60	NIXrWY9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGrMUoQzPCCqcoO=		MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwNUmg{txONg>?	NUHy[Ic{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVQ6OThpPkK5OFU1QTF6PD;hQi=>
MDA-MB-435	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnTKNlQhcHK\|		MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01OzViY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFEvPzhizszNMi=>	M2jLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW0PVE5Lz5{OUS1OFkyQDxxYU6=
K562	MWLGeY5kfGmxbjDhd5NigQ>?				NWrZTWVZUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KHCjcoTpZYxtgSCydYLp[olm\CCqaYP0c45mKGSnYXPleJlt[XOnIH;mJIh2dWGwIHzleYtmdWmjIFu1OlIh[2WubIOuMEBKSzVyIE2gNE4xODR4IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR{NUGxNEc,OTB2MkWxNVA9N2F-
A20	M2HvRWZ2dmO2aX;uJIF{e2G7				NWLjZVZHUW5idnn0do8h\m:{IHHueIkuUESDQ{GgLGhqe3SxbnWg[IVi[2W2eXzhd4UhOSliYXP0bZZqfHliaX6gcY92e2ViQUKwJINmdGy\|LDDJR\|UxKD1iMD6wNFIh\|ryPLh?=	NWXKWIttRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG5OlA1QDlpPkGxPVYxPDh7PD;hQi=>
K 562	MXjGeY5kfGmxbjDhd5NigQ>?				M1nl[2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJcXO2b37lJIRm[WOndInsZZNmKCiKRFHDLUBqdiCNIEW2NkBmenm2aILvcIV2c2WvaXGgZ4VtdHNuIFnDOVAhRSByLkCwN\|Qh\|ryPLh?=	M33GXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmyOFc{Lz5zNEW5NlQ4OzxxYU6=
friend cell	NVzFcJJiTnWwY4Tpc44h[XO\|YYm=				NGDWfWRKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDmdolmdmRiY3XscJMheHKxbHnm[ZJifGmxbjygTWM2OCB;IECuNFQh\|ryPLh?=	Ml;vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR4MUOzNVIoRjF2NkGzN\|EzRC:jPh?=
SNU-16	MXnGeY5kfGmxbjDhd5NigQ>?				M1HMXmlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJcXO2b37lJIRm[WOndInsZZNmKCiKRFHDLUBnem:vIGPOWU0yPiBqaIXtZY4h\2G\|dILpZ{Bi\GWwb3PhdoNqdm:vYTmgZ4VtdHNuIFnDOVAhRSByLkC1N\|I6KM7:TT6=	NHrJd2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[2O\|IzPyd-MUS2OlczOjd:L3G+
melanoma B16/BL6	MlnZSpVv[3Srb36gZZN{[Xl?				NEPWd4VKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhcGm\|dH;u[UBl\WGlZYT5cIF{\XNiKFjERWMyMSCycnXwZZJm\CCocn;tJI1wfXOnIH3lcIFvd22jIFKxOk9DVDZiY3XscJMtKEmFNUCgQUAxNjBzOTFOwG0v	NISycnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGwPVYzPid-MUWxNFk3OjZ:L3G+
melanoma B16/BL6	NV3meGRLTnWwY4Tpc44h[XO\|YYm=				NVrxeFl1UW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWM1MSCycnXwZZJm\CCocn;tJI1wfXOnIH3lcIFvd22jIFKxOk9DVDZiY3XscJMtKEmFNUCgQUAxNjB{IN88UU4>	M3L1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlI3Lz5zNUGwPVYzPjxxYU6=
melanoma B16/BL6	MWTGeY5kfGmxbjDhd5NigQ>?				M{DYNWlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpcXO2b37lJIRm[WOndInsZZNmKDZicILldIFz\WRiZoLvcUBud3W\|ZTDt[Yxidm:vYTDCNVYwSkx4IHPlcIx{NCCLQ{WwJF0hOC5yMkig{txONg>?	NFm5cpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGwPVYzPid-MUWxNFk3OjZ:L3G+
melanoma B16/BL6	NUPJVJlNTnWwY4Tpc44h[XO\|YYm=				Mk\FTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JIhqe3SxbnWg[IVi[2W2eXzhd4UhQCCycnXwZZJm\CCocn;tJI1wfXOnIH3lcIFvd22jIFKxOk9DVDZiY3XscJMtKEmFNUCgQUAxNjB2IN88UU4>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTFyOU[yOkc,OTVzMEm2NlY9N2F-
293T	M4\FdWZ2dmO2aX;uJIF{e2G7				NEW2VnlKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViNDDwdoVx[XKnZDDmdo9uKDJ7M2SgZ4VtdHNuIFnDOVAhRSByLkCyJO69VS5?	NXO2dVhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzOjRpPkG1OFU1OjJ2PD;hQi=>
293T	NFvuSVNHfW6ldHnvckBie3OjeR?=				NFnud\|VKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViMTDwdoVx[XKnZDDmdo9uKDJ7M2SgZ4VtdHNuIFnDOVAhRSByLkCyJO69VS5?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTR3NEKyOEc,OTV2NUSyNlQ9N2F-
293T	M2CwTWZ2dmO2aX;uJIF{e2G7				NVfoTmRQUW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIE[gdJJmeGG{ZXSg[pJwdSB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wNkDPxE1w	M{TadFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NEW0NlI1Lz5zNUS1OFIzPDxxYU6=
293T	NH;yW5ZHfW6ldHnvckBie3OjeR?=				Ml;kTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKDhicILldIFz\WRiZoLvcUAzQTOWIHPlcIx{NCCLQ{WwJF0hOC5yNDFOwG0v	M1nrU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NEW0NlI1Lz5zNUS1OFIzPDxxYU6=
HeLa	NVfkZZNDTnWwY4Tpc44h[XO\|YYm=				MnPJTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{kh\nKxbTDI[WxiKGOnbHzzJJdqfGhic4Xid5Rz[XSnIEXhMEBKSzVyIE2gNE4xPTR3IN88UU4>	NGXoNY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OlI3Pyd-MUW0OVYzPjd:L3G+
HCT116	NGToVoxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				Mn;3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDIR3QyOTZiY3XscJMtKEmFNUCgQUAxNjByMUOg{txONg>?	MoLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MES4PVAoRjF4OUC0PFkxRC:jPh?=
H1299	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				MoXMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDINVI6QSClZXzsd{whUUN3MDC9JFAvOSEQvF2u	Mn30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MES4PVAoRjF4OUC0PFkxRC:jPh?=
H661	Ml[wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NFLhUJVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGg3PjFiY3XscJMtKEmFNUCgQUAxNjNizszNMi=>	NUK2OpR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NFQ5QTBpPkG2PVA1QDlyPD;hQi=>
H661	NIn1XItCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEXa[5U1QCCqcoO=		NHjQN3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGg3PjFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvODh3IN88UU4>	NVKxZ24{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlQ4PzNpPkG3OlI1Pzd\|PD;hQi=>
WiDr	NV3obo42T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NHHsNXhKdmirYnn0bY9vKG:oIGPBVFE{OCCvZXTpZZRm\CClZXzsJIdzd3e2aDDpckBpfW2jbjDXbWRzKGOnbHzzMEBKSzVyIE2gNE42Pzd4IN88UU4>	M4WySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkSzNVEzLz5zN{[0N\|EyOjxxYU6=
U251	MV7GeY5kfGmxbjDhd5NigQ>?				MX\Jcohq[mm2aX;uJI9nKFODUEGzNEBqdiCYRVfGMZN1cW23bHH0[YQhcHWvYX6gWVI2OSClZXzsd{BjgSCSTFHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjZzMUKg{txONg>?	M3LRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkSzNVEzLz5zN{[0N\|EyOjxxYU6=
293T	NIe3bHBHfW6ldHnvckBie3OjeR?=				M3jOeWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gg[ZhxemW\|c3XkJIlvKDJ7M2SgZ4VtdHNuIFnDOVAhRSByLkCwNVkh\|ryPLh?=	M{TqT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OEixNlMzLz5zN{i4NVI{OjxxYU6=
293T	M4raUGZ2dmO2aX;uJIF{e2G7				M3q4cmlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Sg[ZhxemW\|c3XkJIlvKDJ7M2SgZ4VtdHNuIFnDOVAhRSByLkCwNkDPxE1w	NUnwOW1GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PFEzOzJpPkG3PFgyOjN{PD;hQi=>
293T	Mn7lSpVv[3Srb36gZZN{[Xl?				NIHUWGZKdmirYnn0bY9vKG:oIH3veZNmKEiGQVO2JIV5eHKnc4Pl[EBqdiB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wNFI5KM7:TT6=	NHrWb4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{i4NVI{Oid-MUe4PFEzOzJ:L3G+
H661	Mm\sRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYG0PEBpenN?		NHXCNldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGg3PjFiY3XscJMh[W[2ZYKgOFghcHK\|LDDJR\|UxKD1iMD6wPFUh\|ryPLh?=	NXfzdnlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PVc5OjRpPkG3PFk4QDJ2PD;hQi=>
293T	MorQSpVv[3Srb36gZZN{[Xl?				NYPxS2d2UW6qaXLpeIlwdiCxZjDISGFEOSCneIDy[ZN{\WRiaX6gNlk{XCClZXzsd{whUUN3MDC9JFAvOTlizszNMi=>	NVniOWJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5NFA6OTFpPkG3PVAxQTFzPD;hQi=>
293T	NHi0eWdHfW6ldHnvckBie3OjeR?=				Mni0TY5pcWKrdHnvckBw\iCKRFHDOEBmgHC{ZYPz[YQhcW5iMkmzWEBk\WyuczygTWM2OCB;IECuNkDPxE1w	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzlyMEmxNUc,OTd7MEC5NVE9N2F-
293T	NIToW25HfW6ldHnvckBie3OjeR?=				MoflTY5pcWKrdHnvckBw\iCKRFHDOkBmgHC{ZYPz[YQhcW5iMkmzWEBk\WyuczygTWM2OCB;IECuNlgh\|ryPLh?=	NHrie2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mwNFkyOSd-MUe5NFA6OTF:L3G+
NIH3T3	NFvqdoNHfW6ldHnvckBie3OjeR?=				NXrQfXIyUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSCneIDy[ZN{\WRiaX6gUmlJO1R\|IHPlcIx{NCCLQ{WwJF0hOC5yMkGg{txONg>?	NHnEfHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{myPVc6QCd-MUe5Nlk4QTh:L3G+
human 293	NGWyPVZHfW6ldHnvckBie3OjeR?=				Ml3tTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOEBmgHC{ZYPz[YQhcW5iMkmzJINmdGy\|LDDJR\|UxKD1iMD6wN\|Qh\|ryPLh?=	M1fmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUK5O\|k5Lz5zN{myPVc6QDxxYU6=
mouse 293	NHLDVJhHfW6ldHnvckBie3OjeR?=				NGTsOoVKdmirYnn0bY9vKG:oIH3veZNmKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nm\CCrbjCyPVMh[2WubIOsJGlEPTBiPTCwMlA5OSEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl{OUe5PEc,OTd7Mkm3PVg9N2F-
SKBR3	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				M3LzTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vCVlMh[2WubIOsJGlEPTBiPTCwMlAzKM7:TT6=	Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
MM96L	M1HaVGZ2dmO2aX;uJIF{e2G7				M1riRmlvcGmkaYTpc44hd2ZiaIXtZY4hVU17NlygZ4VtdHNuIFnDOVAhRSByLkCzJO69VS5?	NXmzVYk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
SNU16	MXnGeY5kfGmxbjDhd5NigQ>?				MmXpTY5pcWKrdHnvckBw\iCKRFHDJIZzd21iaIXtZY4hW06XMU[gZ4VtdHNuIFnDOVAhRSByLkC1N{DPxE1w	NH:3[YU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
A549	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NVniOZNtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE4xQCEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
MKN45	MnW5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MkTtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPS160OUBk\WyuczygTWM2OCB;IECuNUDPxE1w	NUj0NG56RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
SQ20B	MUHGeY5kfGmxbjDhd5NigQ>?				NUPaUYw{UW6qaXLpeIlwdiCxZjDoeY1idiCVUUKwRkBk\WyuczygTWM2OCB;IECuNkDPxE1w	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
neonatal foreskin fibroblasts	M3fVSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MX3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDu[Y9v[XSjbDDmc5Jme2urbjDmbYJzd2KuYYP0d{Bk\WyuczygTWM2OCB;IECuNkDPxE1w	M3nTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
HeLa	MmKySpVv[3Srb36gZZN{[Xl?				NW\SfYRJUW6qaXLpeIlwdiCxZjDISGFEKG[{b32gbJVu[W5iSHXMZUBk\WyuczygTWM2OCB;IECuN{DPxE1w	NXXFVVhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
MM96L/NFF	M4HQXGZ2dmO2aX;uJIF{e2G7				MnT5V4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJIh2dWGwIF3NPVZNKGOnbHzzJJRwKEmFNUCg[o9zKGi3bXHuJG5HTiClZXzsd{whUUN3MDC9JFYvPyEQvF2u	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
293T	NX\XW205TnWwY4Tpc44h[XO\|YYm=				MWDJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIHX4dJJme3OnZDDpckAzQTOWIHPlcIx{NCCLQ{WwJF0hOC5yM{[2JO69VS5?	NH7Be2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5O\|gzPid-MUizPVc5OjZ:L3G+
293T	MknMSpVv[3Srb36gZZN{[Xl?				NISxVIVKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0JIV5eHKnc4Pl[EBqdiB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wOlI6KM7:TT6=	MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OUe4NlYoRjF6M{m3PFI3RC:jPh?=
293T	NUDuPFhFTnWwY4Tpc44h[XO\|YYm=				NGHnXJRKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO2JIV5eHKnc4Pl[EBqdiB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wPFM{KM7:TT6=	M3G5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{m3PFI3Lz5zOEO5O\|gzPjxxYU6=
HeLa	M4XVNWZ2dmO2aX;uJIF{e2G7				M1v2XWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQzDpckBJ\UyjIHPlcIx{KGK7IH\sc5VzKGSnIHz5d{Bie3OjeTygTWM2OCB;IECuNFA2KM7:TT6=	NH21VWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5O\|gzPyd-MUizPVc5Ojd:L3G+
S2	M{fFNGZ2dmO2aX;uJIF{e2G7				MofqTY5pcWKrdHnvckBw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gTGRCSzFiZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy\|LDDJR\|UxKD1iMD6wNFA3KM7:TT6=	M{jIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{G3OFUxLz5zOUOxO\|Q2ODxxYU6=
NCI-H661	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1\NWFQ5KGi{cx?=		M4ixR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg3PjFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|OEW2NFAoRjF7M{i1OlAxRC:jPh?=
NIH3T3	MVrGeY5kfGmxbjDhd5NigQ>?				MUfJcohq[mm2aX;uJI9nKEiGQVOxJIlvKGi3bXHuJG5KUDOWMzDj[YxteyCkeTDyZYRqd22ndILpZ{BpcXO2b37lJIRm[WOndInsZZRqd25iYYPzZZktKEmFNUCgQUAxNjByNjFOwG0v	NHSydGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS1O\|Y2QSd-MUm0OVc3PTl:L3G+
HeLa	MWTGeY5kfGmxbjDhd5NigQ>?				MUXJcohq[mm2aX;uJI9nKEiGQVOg[pJwdSCqdX3hckBJ\UyjIHPlcIx{KGK7IH\seY9zd2enbnnjJIVvgnmvZTDhd5NigSxiSVO1NEA:KDBwMzFOwG0v	NX;HeWk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OVc3PTlpPkG5OFU4PjV7PD;hQi=>
ML1	MnHBRY51cXS3bX;yJIF{e2G7				MYfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCPTEGgZ4VtdHNuIFnDOVAhRSByLkK1JO69VS5?	NX3FR3lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|Q2OzRpPkG5OVM1PTN2PD;hQi=>
HCT116	MlntR5l1d3SxeHnjbZR6KGG\|c3H5		NVKwXYJFOyCmYYnz		MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwJF0hOC56IN88UU4>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MkKyOkc,OjB2NUKyNlY9N2F-
HCT116	NEOwdnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHG2b2Q1QCCqcoO=		MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODR\|IN88UU4>	MmjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyN{OxOlAoRjJzMEezNVYxRC:jPh?=
H460	M4jMcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3T3S\|Q5KGi{cx?=		M{O4cWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGg1PjBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5M{G2NEc,OjFyN{OxOlA9N2F-
DMS53	M1nncGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEfxe2czKGSjeYO=		MWDDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF3TOVMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiMjDkZZl{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFI2KM7:TT6=	MofLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MESyNVQoRjJzNUC0NlE1RC:jPh?=
HeLa	M3i3UmZ2dmO2aX;uJIF{e2G7		MnTDNlAhdWmwcx?=		M1yyXWlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJ\UyjIHPlcIx{KHW\|aX7nJGFkNUG{Zz3HcJkuVHm\|KFHjLU1CVUNiYYOg[ox2d3Knc3PlcpQhe3Wkc4TyZZRmKGGodHXyJFIxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>?	M3\IUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkKxPFg{Lz5{MU[yNVg5OzxxYU6=
Sf9	MmnkSpVv[3Srb36gZZN{[Xl?		NELEcYQyKGi{		MWjJcohq[mm2aX;uJI9nKE5idHXycYlv[WxiaHX4ZYhqe3SrZHnu[U11[WepZXSgbJVu[W5iSFTBR\|gh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDh[pRmeiBzIHjyJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwOU[g{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd{M{ezN{c,OjF5MkO3N\|M9N2F-
MCF7	M1HxTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mkn3OFghcHK\|		MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNzFOwG0v	NUnjS3FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlUxQTFpPkKyOFY2ODlzPD;hQi=>
BE(2)-C	MmXtRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1XvV\|czKGi{cx?=		NHm3dlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLFLFIqNUNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xPSEQvF2u	Mlf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7M{KzNVYoRjJ{OUOyN\|E3RC:jPh?=
Sf9	NUPmOHVtTnWwY4Tpc44h[XO\|YYm=		MmKwNkBpenN?		NYrvdJhzUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIlv[3WkYYTl[EBnd3JiMjDodpMhfXOrbnegVmhMUy2DYzDmcJVwem:pZX7pZ{B{fWK\|dILheIUtKEmFNUCgQUAxNjByMUKg{txONg>?	NVfDdXZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFkzODNpPkKzNFA6OjB\|PD;hQi=>
Sf9	MVHGeY5kfGmxbjDhd5NigQ>?		M1e5clIhcHK\|		NHnCWGVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgbY5kfWKjdHXkJIZweiB{IHjyd{B2e2mwZzDSTGtMNUGlIH\seY9zd2enbnnjJJN2[nO2cnH0[UwhUUN3MDC9JFAvODB3IN88UU4>	M2nrPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEC5NlA{Lz5{M{CwPVIxOzxxYU6=
A2780	NILpZmNEgXSxdH;4bYNqfHliYYPzZZk>		NF7sd4g4OiCqcoO=		Ml:4R5l1d3SxeHnjbZR6KGGpYXnud5Qh[2m\|cHzheIlvKHKnc3nzeIFvfCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{MjFOwG0v	NISySWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
A2780	M4HHRWZ2dmO2aX;uJIF{e2G7		M3\Ie\|E5KGi{cx?=		MUDJcohq[mm2aX;uJI9nKEiGQVOgbY4h[2m\|cHzheIlvKHKnc3nzeIFvfCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAyQCCqcoOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5{NTFOwG0v	MmjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
A2780	MkTOR5l1d3SxeHnjbZR6KGG\|c3H5		NX7mS5NMPzJiaILz		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4zQSEQvF2u	Ml2wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
A2780	MnSzSpVv[3Srb36gZZN{[Xl?		MXSxPEBpenN?		M3rIR2lvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBCOjd6MDDj[YxteyCjZoTldkAyQCCqcoOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC52MzFOwG0v	MmHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
Sf9	MU\GeY5kfGmxbjDhd5NigQ>?				MVHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz;z[lkh[2WubIOgeZNqdmdiUljLT2FkKGG\|IIP1ZpN1emG2ZTygTWM2OCB;IECuNFAxQSEQvF2u	NUnXd3l5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
Sf9	MWfGeY5kfGmxbjDhd5NigQ>?				MnPnTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOvd4Y6KGOnbHzzJJV{cW6pIGLIT2tC[yCjczDzeYJ{fHKjdHWsJGlEPTBiPTCwMlAxPSEQvF2u	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEW2PFAoRjJ\|OUC1OlgxRC:jPh?=
Sf9	NXzJS4JwTnWwY4Tpc44h[XO\|YYm=				MWDJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOyJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz;z[lkh[2WubIOgeZNqdmdiUljLT2FkKGG\|IIP1ZpN1emG2ZTygTWM2OCB;IECuNFA2KM7:TT6=	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEW2PFAoRjJ\|OUC1OlgxRC:jPh?=
Sf9	M4n0ZmZ2dmO2aX;uJIF{e2G7				MWnJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxNEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOvd4Y6KGOnbHzzJJV{cW6pIGLIT2tC[yCjczDzeYJ{fHKjdHWsJGlEPTBiPTCwMlAxQSEQvF2u	NVy1NFVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
Sf9	NXf5XGg1TnWwY4Tpc44h[XO\|YYm=				M{H6O2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|EyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{9{\jliY3XscJMhfXOrbnegVmhMU0GlIHHzJJN2[nO2cnH0[UwhUUN3MDC9JFAvODF5MzFOwG0v	M{[xTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUC1OlgxLz5{M{mwOVY5ODxxYU6=
Sf9	NWXTd4xNTnWwY4Tpc44h[XO\|YYm=				NX;x[lZXUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQCCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMwe2Z7IHPlcIx{KHW\|aX7nJHJJU0GlS1HjJIF{KHO3YoP0doF1\SxiSVO1NEA:KDBwMUK5JO69VS5?	M1W4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUC1OlgxLz5{M{mwOVY5ODxxYU6=
MOLT4	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		NXfSc3l3PzJiaILz		Mn;LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUW9NXDRiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6wN{DPxE1w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
A549	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		NUnLcJo4PzJiaILz		MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>?	M4i2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[wOlI4Lz5{NEm2NFYzPzxxYU6=
MCF7	NYTieXpKS3m2b4TvfIlkcXS7IHHzd4F6		MWG3NkBpenN?		MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwME[g{txONg>?	NX\sWGluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlA3OjdpPkK0PVYxPjJ5PD;hQi=>
HL60	Mon0R5l1d3SxeHnjbZR6KGG\|c3H5		NWrMTYxsPzJiaILz		MkHZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSByLkC4JO69VS5?	M2LEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[wOlI4Lz5{NEm2NFYzPzxxYU6=
BGC823	M2W1OGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIXKbVM4OiCqcoO=		NHi1NFlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4xQCEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
HuH7	M{POdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUPFWXpJPzJiaILz		MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	NVvhcFdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlA3OjdpPkK0PVYxPjJ5PD;hQi=>
U937	M3PXTGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGj3VFQ4OiCqcoO=		MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
HeLa	NGXkUXFEgXSxdH;4bYNqfHliYYPzZZk>		NXm5PHZCPzJiaILz		M2q1fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6xNUDPxE1w	NV[3RmF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlA3OjdpPkK0PVYxPjJ5PD;hQi=>
NCI-H1975	M1zVWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWW2XZdNPzJiaILz		MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4zOSEQvF2u	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
K562	MlvmR5l1d3SxeHnjbZR6KGG\|c3H5		NHT2cVE4OiCqcoO=		MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwNEGg{txONg>?	MmnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkC2NlcoRjJ2OU[wOlI4RC:jPh?=
HEK293	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		MX:5OkBpenN?		M2PWSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7MzDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zNjFOwG0v	NVLzfYhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVYyODJpPkK1OVU3OTB{PD;hQi=>
LO2	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		MoC2PVYhcHK\|		MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMU\|Ih[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNlEh\|ryPLh?=	M3i2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW2NVAzLz5{NUW1OlExOjxxYU6=
HeLa	M4DvTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnP0PVYhcHK\|		M4L1PGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvQDVizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NkGwNkc,OjV3NU[xNFI9N2F-
HepG2	NU\rb4VHS3m2b4TvfIlkcXS7IHHzd4F6		MVS5OkBpenN?		MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE46PiEQvF2u	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NkGwNkc,OjV3NU[xNFI9N2F-
U2OS	M1njWGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2G1Tlk3KGi{cx?=		NXj4Vm84S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTKRUzDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTRwOUOg{txONg>?	NGPBOnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OlExOid-MkW1OVYyODJ:L3G+
Sf9	MkLiSpVv[3Srb36gZZN{[Xl?		MnTkPVAhdWmwcx?=		NWH4[WpmUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBPNXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|YhMDFidH:gNVIyPSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{B2e2mwZzDSTGsuUyiDYzmtRW1EKGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDlyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wNFE4OTZizszNMi=>	MnfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlQoRjJ5ME[wO\|Y1RC:jPh?=
Sf21	M3ThOmZ2dmO2aX;uJIF{e2G7		MkHNOlAhdWmwcx?=		NHz5WIxKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIILlZ49u[mmwYX70JGMufGW{bXnuZYwhTkyDRz3IbZMufGGpZ3XkJGhFSUNzIDixJJRwKDR6MjDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKFOoMkGgZ4VtdHNidYPpcochWkiNLVuoRYMqNUGPQzDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjC2NEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB4NUe0JO69VS5?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2OEc,OjdyNkC3OlQ9N2F-
insect cell	MkiwSpVv[3Srb36gZZN{[Xl?		MnH1OlAhdWmwcx?=		NV3X[3MxUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|IhMDFidH:gOFg5KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW\|aX7nJHJJUy2NKFHjLU1CVUNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiNkCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAyODVzIN88UU4>	MkTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlQoRjJ5ME[wO\|Y1RC:jPh?=
insect cell	NF\aOnVHfW6ldHnvckBie3OjeR?=		NEDDWnI3OCCvaX7z		NYDQZoR3UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKEircz30ZYdo\WRiSFTBR\|MhMDFidH:gOFI5KHKnc3nkeYV{MS:qdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgUmNQWjJiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{BTUEtvSzjBZ{kuSU2FIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IE[wJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOTFyNzFOwG0v	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2OEc,OjdyNkC3OlQ9N2F-
insect cell	NVruTotyTnWwY4Tpc44h[XO\|YYm=				NGPrSZhKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygTIl{NXSjZ3fl[EBJTEGFMUGgLFEhfG9iM{S3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzM4Ji[3Wub4\pdpV{KGW6cILld5Nqd25ic4nzeIVuKHW\|aX7nJHJJUy2NKFHjLU1CVUNiYYOgd5Vje3S{YYTlJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMEGxN\|ch\|ryPLh?=	MoXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlQoRjJ5ME[wO\|Y1RC:jPh?=
insect cell	M2TwW2Z2dmO2aX;uJIF{e2G7		M3LlSFYxKG2rboO=		MkPGTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCFLYTldo1qdmGuIFjpd{11[WepZXSgTGRCSzhiKEGgeI8hOzd5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hcW6\|ZXP0JINmdGy\|IIXzbY5oKFKKSz3LLGFkMS2NKFHjLU1CVUNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiNkCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlMxPzRizszNMi=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2OEc,OjdyNkC3OlQ9N2F-
SHSY5Y	M3TLbmZ2dmO2aX;uJIF{e2G7		NFzVeFA5KGi{cx?=		NYPoRlB6UW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCVSGPZOXkh[2WubIOgeZNqdmdiQlHUR3Ah[XNic4Xid5Rz[XSnIHHmeIVzKDhiaILzJIJ6KFWKUFzDMWVUUS2PUz;NV{BidmGueYPpd{whUUN3MDC9JFAvODB5ODFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ3MEmyOUc,Ojd4NUC5NlU9N2F-
SHSY5Y	NWGyZYpXTnWwY4Tpc44h[XO\|YYm=		MkSyPEBpenN?		NYK5WGl{UW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKFOKU2m1XUBk\WyuczD1d4lv\yCPQVygZZMhe3Wkc4TyZZRmKGGodHXyJFghcHK\|IHL5JHVJWEyFLVXTTU1OWy:PUzDhcoFtgXOrczygTWM2OCB;IECuNFA6OSEQvF2u	Mm\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4NUC5NlUoRjJ5NkWwPVI2RC:jPh?=
Sf9	NIO5[INHfW6ldHnvckBie3OjeR?=		MXW0JIhzew>?		NHLzW3JKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFfTWE11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegUW9EWEGFIHHzJJN2[nO2cnH0[UBi\nSncjC0JIhzeyCkeTDVTHBNSy2HU1mtUXMwVVNiYX7hcJl{cXNuIFnDOVAhRSByLkCxOVch\|ryPLh?=	NUDBWJcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OVA6OjVpPkK3OlUxQTJ3PD;hQi=>
insect cell	NITjXmxHfW6ldHnvckBie3OjeR?=		MWK0JIhzew>?		MlnITY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KHW\|aX7nJGJCXEOSIHHzJJN2[nO2cnH0[UBi\nSncjC0JIhzeyCkeTDVTHBNSy2HU1mtUXMwVVNiYX7hcJl{cXNuIFnDOVAhRSByLkCxOkDPxE1w	NGSzUmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[1NFkzPSd-Mke2OVA6OjV:L3G+
SHSY5Y	NHXqcpdHfW6ldHnvckBie3OjeR?=		MWq4JIhzew>?		M1zNeWlvcGmkaYTpc44hd2ZiSFTBR\|EhcW5iaIXtZY4hW0iVWUXZJINmdGy\|IIXzbY5oKE2RQ2DBR{BieyC\|dXLzeJJifGViYX\0[ZIhQCCqcoOgZpkhXUiSTFOtSXNKNU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOTh6IN88UU4>	NV3VT5hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OVA6OjVpPkK3OlUxQTJ3PD;hQi=>
HEK293T	M2rQRWZ2dmO2aX;uJIF{e2G7		M2TzOVMxKG2rboO=		MV7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEiGQVOxJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJJV{cW6pIFHjMWtIVEeNKFHjLU1OS0FiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiaX6gdJJme2WwY3Wgc4YhTFSWIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF7IN88UU4>	NUjP[XR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVk3ODRpPkK5OVE6PjB2PD;hQi=>
HEK293T	NHO4R5JHfW6ldHnvckBie3OjeR?=		M1LoelMxKG2rboO=		MnTuTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDtc5V{\SCKRFHDOkBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{Bkdy2neIDy[ZN{cW6pIH3veZNmKEiGQUKgeZNqdmdiQXOtT2dNT0tqQXOpMW1ESSCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCrbjDwdoV{\W6lZTDv[kBFXFRiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOjhizszNMi=>	M4PN[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG5OlA1Lz5{OUWxPVYxPDxxYU6=
NFF	Ml2yR5l1d3SxeHnjbZR6KGG\|c3H5				MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOsJGlEPTBiPTCwMlIh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2NUSwNkc,OzB{NEW0NFI9N2F-
insect cell	M{LWTGZ2dmO2aX;uJIF{e2G7				Mny0TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gTGRCSzZiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBk\WyuczD1d4lv\yCUSFvLLGFkMUGPQzDhd{B{fWK\|dILheIUh[nliZnz1c5Jme2OnbnPlMYJie2WmIHHzd4F6NCCLQ{WwJF0hOC5yMEi1JO69VS5?	M3jiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
Sf21	NFPt[YVHfW6ldHnvckBie3OjeR?=				MVnJcohq[mm2aX;uJI9nKENvdHXycYlv[WxiRlzBS{1JcXNvdHHn[4VlKG[3bHygcIVv\3SqIILlZ49u[mmwYX70JIh2dWGwIFjERWMyKGW6cILld5Nm\CCrbjDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCUSFvLLGFkMUGPQzDhd{B{fWK\|dILheIUh[nliZnz1c5Jme2OnbnPlMYJie2WmIHHzd4F6NCCLQ{WwJF0hOC5yMEm0JO69VS5?	MknXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
insect cell	MmWxSpVv[3Srb36gZZN{[Xl?				NX7ucFNvUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDISGFEOy:QQ1;SNkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KHW\|aX7nJHJJU0tqQXOpRW1EKGG\|IIP1ZpN1emG2ZTDifUBndHWxcnXzZ4Vv[2VvYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlAyOjdizszNMi=>	MkHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
insect cell	MU\GeY5kfGmxbjDhd5NigQ>?				MYDJcohq[mm2aX;uJI9nKENvdHXycYlv[WxiR2PUMZRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjDISGFEOiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IIXzbY5oKFKKS1uoRYMqSU2FIHHzJJN2[nO2cnH0[UBjgSCobIXvdoV{[2WwY3WtZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{Nkeg{txONg>?	NIq5OHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
insect cell	MVjGeY5kfGmxbjDhd5NigQ>?				M4DIPGlvcGmkaYTpc44hd2ZiQz30[ZJucW6jbDDIbZMufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJGhFSUN6IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiUljLT{hC[ymDTVOgZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[U1j[XOnZDDhd5NigSxiSVO1NEA:KDBwNkC5JO69VS5?	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
A20	MoruSpVv[3Srb36gZZN{[Xl?				M3;yUmJqdmSrbnegZYZncW6rdImgeI94[XKmczDISGFEOSBqSHnzeI9v\SCmZXHj[ZR6dGG\|ZTCxLUBqdiCvb4Xz[UBCOjBiY3XscJMtKGW6cILld5Nm\CCjczDibY5lcW6pIHPvcpN1[W62IDjwT4kqNCCNaTC9JFAvODBzMEeyJO69VS5?	M3TNVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzOU[wOFg6Lz5zMUm2NFQ5QTxxYU6=
Hela	MYfGeY5kfGmxbjDhd5NigQ>?				MkHSTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmdGFiY3XscJMhdnWlbHXhdkBmgHS{YXP0d{BjgSCobIXvdolu\XS{aXOgZZN{[XluIFvpJF0hOC53MESg{txONg>?	M1XscVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUKwOVgxLz5zOUWyNFU5ODxxYU6=
Sf9	MnLzSpVv[3Srb36gZZN{[Xl?		MVW5NEBucW6\|		MYrJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBJTEGFNjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BTUEuNKFHjLWFOSyCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDmcJVwemmvZYTldkwhU2liPTCwMlAxODV6IN88UU4>	NWK0V2FIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1PFk1PDFpPkK5OVg6PDRzPD;hQi=>
Sf21	NV3JeIxPTnWwY4Tpc44h[XO\|YYm=		NYH0enZxPjBibXnudy=>		MWjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKENvdHXycYlv[WxiRlzBS{9JcXNvdHHn[4VlKEiGQVOxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCUSFvLLGFkMUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgOlAhdWmwczDifUBndHWxcnnt[ZRmeixiS3mgQUAxNjByME[0JO69VS5?	M17LdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUi5OFQyLz5{OUW4PVQ1OTxxYU6=
insect cell	MofKSpVv[3Srb36gZZN{[Xl?		Ml7xOlAhdWmwcx?=		NELIWGNKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGMufGW{bXnuZYwhUGm\|LYTh[4dm\CCKRFHDN{9PNXSncn3pcoFtKEeVVD30ZYdo\WRicnXjc41jcW6jboSgbJVu[W5iTlPPVlIhMDN7NTD0c{A1QDlicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCrboPlZ5Qh[2WubIOgeZNqdmdiUljLT{hC[ymDTVOgZZMhe3Wkc4TyZZRmKGGodHXyJFYxKG2rboOgZpkh\my3b4LpcYV1\XJuIFvpJF0hOC5yMEC4OEDPxE1w	NVnqOFV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1PFk1PDFpPkK5OVg6PDRzPD;hQi=>
insect cell	MW\GeY5kfGmxbjDhd5NigQ>?		NVL1e41QPjBibXnudy=>		MWjJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIILlZ49u[mmwYX70JIh2dWGwIFOteIVzdWmwYXygS3NVNXSjZ3fl[EBJTEGFMjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJJV{cW6pIGLIT2spSWNrQV3DJIF{KHO3YoP0doF1\SCjZoTldkA3OCCvaX7zJIJ6KG[udX;ybY1mfGW{LDDLbUA:KDBwMECzOVUh\|ryPLh?=	NHXMbWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW4PVQ1OSd-Mkm1PFk1PDF:L3G+
insect cell	NVv1W5hGTnWwY4Tpc44h[XO\|YYm=				MXrJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEiGQVOxNEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOtbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KHW\|aX7nJIZtfW:{b3flcolkKHCncITp[IUhWkiNS1HjJIF{KHO3YoP0doF1\SCkeTDmcJVwemmvZYTldkwhU2liPTCwMlAxPDd4IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
insect cell	MlzDSpVv[3Srb36gZZN{[Xl?		NX7MR\|RmPjBibXnudy=>		MoDCTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCFLYTldo1qdmGuIFjpd{11[WepZXSgTGRCSzhiKEGgeI8hOzd5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJJV{cW6pIGLIT{hC[ymNKFHjLWFOSyCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDmcJVwemmvZYTldkwhU2liPTCwMlE1PSEQvF2u	MmTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
insect cell	NVPoU5JMTnWwY4Tpc44h[XO\|YYm=				MX\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiSHnzMZRi\2enZDDISGFEOTFiKEGgeI8hOzR5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJJV{cW6pIGLIT2spSWNrQV3DJIF{KHO3YoP0doF1\SCkeTDmcJVwemmvZYTldkwhU2liPTCwMlQxOSEQvF2u	NXvNNZNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1PFk1PDFpPkK5OVg6PDRzPD;hQi=>
GM15850	NEnBTlZHfW6ldHnvckBie3OjeR?=	MWGwMlEhfU1?	M{XFfFEzKGi{cx?=		NIDGZWJKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hT01zNUi1NEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiC2b4ThcEBi[2W2eXzheIVlKGirc4TvcoUhdGW4ZXygZZQhOC5zIIXNJIFnfGW{IEGyJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M4rVSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
A549	M2TCdWZ2dmO2aX;uJIF{e2G7	NGfaVoYxNjFidV2=			NEnSb4FKdmirYnn0bY9vKG:oIGPJVnQzKGmwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMh[WKrbHn0fUB1dyCrbnT1Z4UhcHmyZYLhZ4V1gWyjdHnvckBw\iC2dXL1cIlvKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BifCByLkGgeW0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF2OUi2NEc,OTdzNEm4OlA9N2F-
ST14A	NULCU3ZyTnWwY4Tpc44h[XO\|YYm=	M1L3V\|c2KG6P			Mo\zTY5lfWO2aX;uJI9nKFKHU2SvUnJUTi2lb4XwcIVlKHKncILld5Nqd25ib3[gcJVkcW[ncnHz[UB1[WepZXSgdoF1KFKHMT;OVnNGKEKGTl[gdJJwdW:2ZYKgZYN1cX[rdImg[ZhxemW\|c3XkJIlvKFOWMUTBJINmdGy\|IHH0JFc2KG6PIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGy3Y3nm[ZJie2ViYXP0bZZqfHl?	Mkj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NkW5PVMoRjF5NU[1PVk{RC:jPh?=
HEK293	MkHmSpVv[3Srb36gZZN{[Xl?	MmHhOlAxKG6P			NGjwclVKdmO{ZXHz[UBqdiCJUmC3PEBxem:2ZXnuJIxmfmWuIHnuJGhGUzJ7MzDj[YxteyCjdDC2NFAhdk1iYomgbY1ufW6xYnzveC=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4NkezNkc,OTd3Nk[3N\|I9N2F-
HEK293	MXrGeY5kfGmxbjDhd5NigQ>?	MkDIOlAxKG6P			NUT6c21qUW6lcnXhd4UhcW5icILveIVqdiCmaYP1cIZq\GViaYPvcYVz[XOnIHzleoVtKGmwIFjFT\|I6OyClZXzsd{BifCB4MECgcm0h[nliaX3teY5w[myxdB?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4NkezNkc,OTd3Nk[3N\|I9N2F-
HeLa	NYnIcFlUTnWwY4Tpc44h[XO\|YYm=	M1vTZ\|EhfU1?	MYWyOEBpenN?		M17nTWlv\HWldHnvckBw\iCyMU[g[ZhxemW\|c3nvckBqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfHSrbne=	MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NEOxNVEoRjF5NkSzNVEyRC:jPh?=
HeLa	MXrGeY5kfGmxbjDhd5NigQ>?	NHezWoIyKHWP	NHThO\|YzPCCqcoO=		MkG3TY5lfWO2aX;uJI9nKHB{NzDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?=	Ml7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NEOxNVEoRjF5NkSzNVEyRC:jPh?=
HeLa	Mn7HSpVv[3Srb36gZZN{[Xl?	NISzbGsyKHWP	NIjEVGQzPCCqcoO=		Mm\HTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?=	M4LTV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkSzNVEyLz5zN{[0N\|EyOTxxYU6=
HCT116	MoDtSpVv[3Srb36gZZN{[Xl?				M1jYbmlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{GgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDX[ZN1\XKwIHLsc5Q>	NXjxemRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwOVQzOzlpPkG4NFU1OjN7PD;hQi=>
HCT116	MVjGeY5kfGmxbjDhd5NigQ>?				MlS0TY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNjDhd5Nme3OnZDDhd{B1fWK3bHnuJIh6eGW{YXPleJlt[XSrb36gbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGK7IGfld5Rmem5iYnzveC=>	M{fCd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEW0NlM6Lz5zOEC1OFI{QTxxYU6=
HEK293 STF	NHPDboNHfW6ldHnvckBie3OjeR?=		M3;XZlI1KGi{cx?=		NEW5V\|NC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQhcW5iSFXLNlk{KFOWRjDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\S2kYYPl[EBt[WO2YYTlJIRmcHmmcn;n[Y5ie2ViYYPzZZk>	M4XtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEKyOlc2Lz5zOUCyNlY4PTxxYU6=
NCI-H661	MmSwSpVv[3Srb36gZZN{[Xl?	M{mxWVMxOCCwTR?=	NV\wcI5XPiCqcoO=		MV\Jcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gUmNKNUh4NkGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiYXPleJlt[XSrb36gZZQhOzByIH7NJIFnfGW{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|OEW2NFAoRjF7M{i1OlAxRC:jPh?=
NCI-H661	NUfkV3p2TnWwY4Tpc44h[XO\|YYm=	MVmzNFAhdk1?	Ml\5OkBpenN?		M17sfWlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBPS0lvSE[2NUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdiCjdDCzNFAhdk1iYX\0[ZIhPiCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NVXNVZMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzPFU3ODBpPkG5N\|g2PjByPD;hQi=>
HL60	NIHhWmlHfW6ldHnvckBie3OjeR?=	M2nIdlIxKHWpL33s	NHTRXVEzPCCqcoO=		MWfJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTGw3OCClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9vKGG2IEKwJJVoN22uIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M2TsbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO0OFcyLz5zOUWzOFQ4OTxxYU6=
primary bronchial epithelial cell	NYjueldbTnWwY4Tpc44h[XO\|YYm=	MXiwMlEhfU1?			NX7oeWhNUW6qaXLpeIlwdiCxZjDISGFEPyCrbjDoeY1idiCycnntZZJ6KGK{b37jbIlidCCncHn0bIVtcWGuIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25iYYSgNE4yKHWP	NIiyRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
MCF7	M4fZcWZ2dmO2aX;uJIF{e2G7	NFXYUmsxNjFidV2=	MmjHNVYhcHK\|		M1L2fGlvcGmkaYTpc44hd2ZiU1nSWFIhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczD0eYJ2dGmwIHj5dIVz[WOndInsZZRqd25iYYSgNE4yKHWPIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4S=	M3nYUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEOwN\|Q{Lz5{MECzNFM1OzxxYU6=
HeLa	NHL3NYhHfW6ldHnvckBie3OjeR?=	NXyyZW1ZOSC3TR?=	M{LIVFExKG2rboO=		NY\3Z4t2UW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEinTHGgZ4VtdHNiYYSgNUB2VSCjZoTldkAyOCCvaX7zJIJ6KG[udX;yc41mfHKrYzDhd5NigQ>?	M1nr[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEW1PFQ5Lz5{MUC1OVg1QDxxYU6=
MCF7	MY\GeY5kfGmxbjDhd5NigQ>?	NXjQOWZGOC53IIXN	NYi1dpVUOjRiaILz		M3jGNGlvcGmkaYTpc44hd2ZiQ3zhd5MhOSCqaYP0c45mKGSnYXPleJlt[XOnIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhfXBvcnXneYxifGmxbjDv[kBxOjFicILveIVqdiCuZY\lcEBifCByLkWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MnrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OECzOlMoRjJ{MkiwN\|Y{RC:jPh?=
MCF7	NUO1SmhRTnWwY4Tpc44h[XO\|YYm=	M3fDb\|AvPSC3TR?=	NGXp[oQzPCCqcoO=		NVTNZ\|BuUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJINp[W6pZTDpckB1fWK3bHnuJIFk\XS7bHH0bY9vKGyndnXsJIF1KDBwNTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6MEO2N{c,OjJ{OECzOlM9N2F-
MCF7	NVPEbINbTnWwY4Tpc44h[XO\|YYm=	MWqwMlUhfU1?	MWeyOEBpenN?		NXG2OnBoUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJVxNXKnZ4XsZZRqd25ib3[gZYNmfHmuYYTl[EBpcXO2b37lJGg{KHC{b4TlbY4hdGW4ZXygZZQhOC53IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M1e3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkiwN\|Y{Lz5{MkK4NFM3OzxxYU6=
PC12	NVPyOFJMTnWwY4Tpc44h[XO\|YYm=	NVvYPVNOOTBidV2=	MUW0PEBpenN?		M33rOWlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5icnH0JHBEOTJiY3XscJMh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gc4YhcGm\|dH;u[UBJOyCjdDCxNEB2VSCjZoTldkA1QCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{BidmGueYPpdy=>	NV;Ib2t{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
PC12	MmL0SpVv[3Srb36gZZN{[Xl?	NIfYfVMyOCC3TR?=	M4\OcVQ5KGi{cx?=		M3\PWmlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5icnH0JHBEOTJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36gZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN?	NVLtUVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
PC12	NX7v[24yTnWwY4Tpc44h[XO\|YYm=	M1jHblExKHWP	NGnLNnE2KGSjeYO=		M3X0fWlv\HWldHnvckBw\iCwZYXybZRmKG:3dHfyc5d1cCCrbjDyZZQhWENzMjDj[YxteyCjdDCxNEB2VSCjZoTldkA2KGSjeYO=	M3nodlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUC1OlgxLz5{M{mwOVY5ODxxYU6=
SH-SY5Y	NEfJZ4ZHfW6ldHnvckBie3OjeR?=	Mn;ONVAhfU1?	Ml\IOUBl[Xm\|		MoXVTY5lfWO2aX;uJI9nKG6ndYLpeIUhd3W2Z4Lve5RpKGmwIHj1cYFvKFOKLWPZOXkh[2WubIOgZZQhOTBidV2gZYZ1\XJiNTDkZZl{	NGrodXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwOVY5OCd-MkO5NFU3QDB:L3G+
A549	NYTsXIxVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	M4rHXVAvPCC3TR?=	NX;sWJh{OjRiaILz		NGToUWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhe2i{dX7r[Y4h[W6mIIPoZZJxKHOqYYDlJIF1KDBwNDD1UUBi\nSncjCyOEBpenNiYomgdIhie2ViY3;ueJJie3RibXnjdo9{[2:yeR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6NEGxNkc,OjV6OESxNVI9N2F-
HeLa	NGS2ToRHfW6ldHnvckBie3OjeR?=				MYXJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNidIXieYxqdiCjY3X0fYxifGmxbjDpcoN2[mG2ZXSg[o9zKG:4ZYLubYdpfCCkeTDpcY12dm:obIXvdoV{[2WwY3WgcYlkem:\|Y3;wbYMh[W6jbInzbZM>	NFTJTnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkyQSd-Mk[2NVE6OTl:L3G+
C127-LT	MVHGeY5kfGmxbjDhd5NigQ>?	MUiyNFAhdk1?	M2\wblI1KGi{cx?=		NIP5VmZKdmirYnn0bY9vKG:oIFjERWMhcW5ibX;1d4UhSzF{Nz3MWEBk\WyuczDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIFXHSnAh\XiycnXzd4lwdiCjdDCyNFAhdk1iYX\0[ZIhOjRiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5	NFH6XFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OlM4Oid-Mk[5PVY{PzJ:L3G+
HeLa nuclear	M4rzXmZ2dmO2aX;uJIF{e2G7	NEHQOJcyOCC2bzCyOUB2VQ>?	Mki0N\|AhdWmwcx?=		M1myd2NwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gTGRCSyCrbjDoeY1idiCKZVzhJI52[2ynYYKgZ4VtdHNiYYSgNVAhfG9iMkWgeW0hfXOrbnegRo9kNWGlZYT5cE1tgXOrbnWtRW1EKGG\|IIP1ZpN1emG2ZTDh[pRmeiB\|MDDtbY5{KGK7IFzpcoV4\WG4ZYKtRpVzcyCybH;0JIFv[Wy7c3nz	M1LQXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUm2N\|czLz5{Nkm5OlM4OjxxYU6=
HeLa	NIq3fYpHfW6ldHnvckBie3OjeR?=	NEDifGkzKHWP	MlnnNlQhcHK\|		NUK3Wok2UW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCKZVzhJINmdGy\|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YhcGm\|dH;u[UBJOyCjdDCyJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NFX6O5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
HN13	MWPGeY5kfGmxbjDhd5NigQ>?		MnOzNlQhcHK\|		MoDrTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhPOTNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJIhqe3SxbnWgTFMhVHm\|OTDhZ4V1gWyjdHnvckBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[Xl?	NX7NUZlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwN\|ExPjZpPkK5NFMyODZ4PD;hQi=>
HeLaS3	NHjNVZZHfW6ldHnvckBie3OjeR?=	MV:xNEB2VQ>?			M{\x[WlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJ\UyjU{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;uJIF1KDFyIIXNJI1m[XO3cnXkJIludWWmaXH0[Yx6KGK7IHntcZVvd2Kub4SgZY5idHm\|aYO=	MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUi1N\|UoRjNyMkW4OVM2RC:jPh?=
HeLaS3	MmnHSpVv[3Srb36gZZN{[Xl?	NUfnemxxOTBidV2=	M1f6[FE3KGi{cx?=		M{LLW2lvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJ\UyjU{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;uJIF1KDFyIIXNJJRz\WG2ZXSg[o9zKDF4IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KGGwZDDt[YF{fXKnZDD1dEB1dyB{NDDodpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NUi1N\|UoRjNyMkW4OVM2RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / STAT3 ; PubMed: 31289542 Oncol Lett Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting. Cyclin D1 / CDK6 / CDK4 / p-RB / RB; PubMed: 31289542 Oncol Lett Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. MMP-1 / MMP-3 / MMP-13 / TIMP-1; PubMed: 27431944 Mol Med Rep Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h. Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); PubMed: 27431944 Mol Med Rep Chondrocytes were treated with increasing concentrations of TSA for 24 h. α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; PubMed: 23802098 Front Oncol Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).	31289542 27431944 23802098
Immunofluorescence	α-C/EBPβ / α-HP1α ; PubMed: 21122806 Exp Cell Res 3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. α-HDAC1 ; PubMed: 29045501 PLoS One MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels. α-tubulin / acetylated histone 3; PubMed: 27957719 Neurotherapeutics Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.	21122806 29045501 27957719
Growth inhibition assay	Cell viability (A549 cells); PubMed: 27571418 PLoS One Cytotoxicity of histamine determined by MTT assay in A549 cells. Cell viability (MDA-MB-231 cells); PubMed: 27548148 Int J Mol Sci The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8. Cell viability (PC3 cells); PubMed: 31289542 Oncol Lett PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.	27571418 27548148 31289542

In vivo

Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. ^[1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro HDAC activity: Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×10⁵ cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 10⁶ cpm) of [³H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [³H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [³H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research: ^[1]	- Collapse Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM Incubation Time: 96 hours Method: Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU Dosages: ~5 mg/kg/day Administration: Injection s.c. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	23 mg/mL (76.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	1.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Trichostatin A (TSA) SDF

Molecular Weight	302.4
Formula	C₁₇H₂₂N₂O₃
CAS No.	58880-19-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04606771	Recruiting	Drug: Osimertinib + Savolitinib\|Drug: Savolitinib + Placebo	Non-Small Cell Lung Cancer	AstraZeneca	September 28 2020	Phase 2
NCT03901053	Recruiting	Device: Reaktiv AFO\|Device: PhatBrace AFO	Foot Injuries and Disorders	Jason Wilken\|Minneapolis Veterans Affairs Medical Center\|Walter Reed National Military Medical Center\|Henry M. Jackson Foundation for the Advancement of Military Medicine\|Center for Veterans Research and Education\|University of Delaware\|Johns Hopkins Bloomberg School of Public Health\|University of Iowa	February 27 2020	Not Applicable
NCT03887650	Recruiting	Drug: Liposomal Bupivicaine 1.3%\|Drug: Bupivacaine 0.5%	Post-operative Pain\|Total Shoulder Arthroplasty\|Osteoarthritis of the Shoulder\|Pain Management	Hartford Hospital	January 14 2019	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?
Answer:
Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)